Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Swallowable robot-camera could spot stomach cancer early

NCT ID NCT07323186

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new, less invasive way to screen for stomach cancer using a magnetic-guided video capsule that patients swallow. The capsule is steered by a robot and uses AI to check the stomach for suspicious spots. Researchers will compare its accuracy to standard endoscopy in 100 adults aged 50-74 who are already having a colonoscopy.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Magnetically controlled video capsule endoscopy (MC-VCE) device
What this could lead to
If successful, this could offer a less invasive, more accessible screening method for early stomach cancer, potentially improving survival rates.
What could go wrong
This is an early-stage study with only 100 participants, and the capsule may miss lesions that standard endoscopy finds. It is not yet proven for widespread screening.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Dec 2025

An estimate. Start dates often move.

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 to 74 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female patient, * Aged between 50 and 74 inclusive with a life expectancy of at least 10 years, * Undergoing screening or surveillance colonoscopy (for colorectal cancer or polyps) * Patient who has received verbal and written information as well as a patient booklet on the VCE-CM examination and has given their written informed consent. * Patient affiliated with a social security scheme * Effective contraception throughout the study for women of childbearing age Exclusion Criteria: * Patients who have had or currently have the following (items from the TOGAS pilot study/specific to endoscope use) will not be included in the study: * An EOGD in a high-volume endoscopy centre within the last 3 years * Known gastric cancer * Known genetic cancer syndromes * Previous gastrectomy or bariatric gastric surgery * Known gastric precancerous condition (gastric atrophy, intestinal metaplasia, dysplasia) * Acute gastrointestinal haemorrhage in the last 4 weeks * A coagulation disorder or medication that prevents biopsy sampling * A risk associated with sedation or anaesthesia * Severe heart disease * An inability to actively consent to participation in the study, and patients under guardianship or legal protection. Pregnant or breastfeeding patients will not be included. Patients with the following conditions (specific to VCE-CM examination) will not be included in the study: * Swallowing disorders or known gastroparesis * A history of digestive surgery * Clinical or radiological signs suggestive of narrowing of the digestive tract * An occlusive or sub-occlusive condition, a known or suspected history of stenosis or digestive fistula * Left heart failure with orthopnoea * Overweight (\> 135 kg) * Reduced mobility (i.e. unable to transfer or move themselves) * Persons with pacemakers, defibrillators or metallic foreign bodies (with the exception of dental implants) will not be included in order to avoid interference with the robot.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diagnosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Nantes University Hospital

    Nantes, 44000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.